Logo image of MTSR

METSERA INC (MTSR) Stock Fundamental Analysis

USA - Nasdaq - NASDAQ:MTSR - US59267L1070 - Common Stock

70.5 USD
-0.25 (-0.35%)
Last: 11/13/2025, 8:00:02 PM
70.65 USD
+0.15 (+0.21%)
After Hours: 11/13/2025, 8:00:02 PM
Fundamental Rating

2

Taking everything into account, MTSR scores 2 out of 10 in our fundamental rating. MTSR was compared to 528 industry peers in the Biotechnology industry. No worries on liquidiy or solvency for MTSR as it has an excellent financial health rating, but there are worries on the profitability. MTSR does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year MTSR has reported negative net income.
MTSR Yearly Net Income VS EBIT VS OCF VS FCFMTSR Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2022 2023 2024 -50M -100M -150M -200M

1.2 Ratios

Looking at the Return On Assets, with a value of -55.41%, MTSR is in line with its industry, outperforming 45.42% of the companies in the same industry.
MTSR has a Return On Equity (-78.90%) which is in line with its industry peers.
Industry RankSector Rank
ROA -55.41%
ROE -78.9%
ROIC N/A
ROA(3y)-26.59%
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
MTSR Yearly ROA, ROE, ROICMTSR Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2022 2023 2024 0 50 -50

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for MTSR so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
MTSR Yearly Profit, Operating, Gross MarginsMTSR Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2022 2023 2024

More info and screens

7

2. Health

2.1 Basic Checks

Compared to 1 year ago, MTSR has about the same amount of shares outstanding.
Compared to 1 year ago, MTSR has a worse debt to assets ratio.
MTSR Yearly Shares OutstandingMTSR Yearly Shares OutstandingYearly Shares Outstanding 2022 2023 2024 20M 40M 60M 80M 100M
MTSR Yearly Total Debt VS Total AssetsMTSR Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2022 2023 2024 100M 200M 300M 400M

2.2 Solvency

An Altman-Z score of 21.41 indicates that MTSR is not in any danger for bankruptcy at the moment.
MTSR has a better Altman-Z score (21.41) than 91.03% of its industry peers.
There is no outstanding debt for MTSR. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 21.41
ROIC/WACCN/A
WACCN/A
MTSR Yearly LT Debt VS Equity VS FCFMTSR Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2022 2023 2024 0 100M -100M 200M

2.3 Liquidity

A Current Ratio of 5.26 indicates that MTSR has no problem at all paying its short term obligations.
With a Current ratio value of 5.26, MTSR perfoms like the industry average, outperforming 58.32% of the companies in the same industry.
MTSR has a Quick Ratio of 5.26. This indicates that MTSR is financially healthy and has no problem in meeting its short term obligations.
MTSR's Quick ratio of 5.26 is in line compared to the rest of the industry. MTSR outperforms 59.63% of its industry peers.
Industry RankSector Rank
Current Ratio 5.26
Quick Ratio 5.26
MTSR Yearly Current Assets VS Current LiabilitesMTSR Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2022 2023 2024 100M 200M 300M

More info and screens

0

3. Growth

3.1 Past

MTSR shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -342.97%.
EPS 1Y (TTM)-342.97%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%N/A
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

Based on estimates for the next years, MTSR will show a decrease in Earnings Per Share. The EPS will decrease by -8.98% on average per year.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y5.94%
EPS Next 2Y-6.07%
EPS Next 3Y-11.11%
EPS Next 5Y-8.98%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
MTSR Yearly Revenue VS EstimatesMTSR Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2028 2029 2030 2031 2032 500M 1B 1.5B 2B 2.5B
MTSR Yearly EPS VS EstimatesMTSR Yearly EPS VS EstimatesYearly EPS VS Estimates 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 2 -2 -4

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for MTSR. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for MTSR. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
MTSR Price Earnings VS Forward Price EarningsMTSR Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
MTSR Per share dataMTSR EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2 4

4.3 Compensation for Growth

MTSR's earnings are expected to decrease with -11.11% in the coming years. This may justify a cheaper valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-6.07%
EPS Next 3Y-11.11%

More info and screens

0

5. Dividend

5.1 Amount

MTSR does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

METSERA INC

NASDAQ:MTSR (11/13/2025, 8:00:02 PM)

After market: 70.65 +0.15 (+0.21%)

70.5

-0.25 (-0.35%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-12 2025-11-12/amc
Earnings (Next)03-24 2026-03-24
Inst Owners84.33%
Inst Owner Change-0.04%
Ins Owners0.91%
Ins Owner Change-751.42%
Market Cap7.43B
Revenue(TTM)N/A
Net Income(TTM)-354.43M
Analysts80
Price Target54.57 (-22.6%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-8.61%
Min EPS beat(2)-18.8%
Max EPS beat(2)1.59%
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-6.69%
PT rev (3m)-6.69%
EPS NQ rev (1m)-1.17%
EPS NQ rev (3m)4.51%
EPS NY rev (1m)0.82%
EPS NY rev (3m)8.86%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 16.54
P/tB 21.2
EV/EBITDA N/A
EPS(TTM)-3.71
EYN/A
EPS(NY)-3.67
Fwd EYN/A
FCF(TTM)N/A
FCFYN/A
OCF(TTM)N/A
OCFYN/A
SpS0
BVpS4.26
TBVpS3.33
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -55.41%
ROE -78.9%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-26.59%
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-ScoreN/A
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 5.26
Quick Ratio 5.26
Altman-Z 21.41
F-ScoreN/A
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-342.97%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%N/A
EPS Next Y5.94%
EPS Next 2Y-6.07%
EPS Next 3Y-11.11%
EPS Next 5Y-8.98%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-571.08%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-130.36%
EBIT Next 3Y-58.08%
EBIT Next 5YN/A
FCF growth 1Y-182.54%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-182.65%
OCF growth 3YN/A
OCF growth 5YN/A

METSERA INC / MTSR FAQ

What is the ChartMill fundamental rating of METSERA INC (MTSR) stock?

ChartMill assigns a fundamental rating of 2 / 10 to MTSR.


What is the valuation status for MTSR stock?

ChartMill assigns a valuation rating of 0 / 10 to METSERA INC (MTSR). This can be considered as Overvalued.


Can you provide the profitability details for METSERA INC?

METSERA INC (MTSR) has a profitability rating of 1 / 10.